Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001065051 | SCV001229989 | pathogenic | Hereditary hemochromatosis | 2023-07-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp781*) in the TFR2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 21 amino acid(s) of the TFR2 protein. This variant is present in population databases (rs768907730, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with hemochromatosis (PMID: 23600741). ClinVar contains an entry for this variant (Variation ID: 859038). This variant disrupts a region of the TFR2 protein in which other variant(s) (p.Gly792Arg) have been determined to be pathogenic (PMID: 16424658, 26029709). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001827421 | SCV004203693 | likely pathogenic | Hemochromatosis type 3 | 2024-02-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001827421 | SCV002079917 | likely pathogenic | Hemochromatosis type 3 | 2020-08-03 | no assertion criteria provided | clinical testing |